Cardiac Fibrosis and Senolytics: What the Research Shows

Cardiac fibrosis — the accumulation of excess collagen in heart tissue — is one of the most consistent features of cardiac aging. It reduces heart muscle compliance, impairs electrical conduction, and contributes to heart failure, arrhythmia, and reduced exercise capacity.

It’s also, based on recent research, meaningfully driven by senescent cells.

Educational content. Not medical advice.

What Cardiac Fibrosis Is

The heart is not a static muscle. It continuously remodels in response to mechanical stress, injury, hormonal signals, and metabolic inputs. Fibrosis occurs when this remodeling balance shifts toward excess extracellular matrix (ECM) deposition — primarily collagen — that stiffens the tissue.

Consequences:

Diastolic dysfunction: The stiff ventricle can’t relax and fill properly (more common than systolic dysfunction in cardiac aging)
Arrhythmia: Fibrotic areas disrupt electrical conduction pathways
Reduced exercise capacity: Stiff heart can’t increase output efficiently in response to demand
Heart failure with preserved ejection fraction (HFpEF): The major form of heart failure in older adults, strongly associated with cardiac fibrosis

Cardiac fibrosis affects virtually everyone to some degree with age — it’s not a binary “have fibrosis or don’t” condition, but a continuous spectrum of tissue stiffening.

Senescent Cells as a Driver of Cardiac Fibrosis

The cardiac fibrosis-senescence connection became clear through several research lines:

Cardiac fibroblasts: The cells responsible for ECM remodeling are fibroblasts. When cardiac fibroblasts become senescent, they don’t go silent — they activate a profibrotic SASP (senescence-associated secretory phenotype) that promotes excessive collagen deposition in surrounding tissue.

Cardiomyocyte senescence: Heart muscle cells (cardiomyocytes) can also enter a senescent state. Senescent cardiomyocytes secrete inflammatory signals that recruit immune cells and activate fibroblasts — another driver of fibrosis.

Immune cell senescence: Macrophages that become senescent lose their ability to efficiently clear damaged matrix proteins and senescent cells — impairing the normal resolution of fibrosis.

The Animal Evidence for Senolytic Cardiac Benefit

The strongest cardiac-specific senolytic data comes from genetic studies (engineered mice where senescent cells can be selectively killed) and pharmacological studies.

Baker et al. 2016 (Nature): Clearing senescent cells in INK-ATTAC mice from midlife onwards produced multiple cardiac benefits including improved cardiac structure and function markers.

Zhu et al. 2015 (Aging Cell): Quercetin + dasatinib treatment in aged mice reduced senescent cell burden in cardiac tissue and improved cardiac function.

2026 DHM Study (Nature Communications): DHM treatment in aged mice specifically reduced:

Cardiac fibrosis markers (Masson’s trichrome staining showed reduced collagen deposition)
Profibrotic signaling proteins (TGF-β, α-SMA)
Inflammatory markers in cardiac tissue

The DHM cardiac fibrosis finding was via the PRDX2 senolytic mechanism — PRDX2 knockout mice showed no cardiac benefit from DHM treatment, confirming the senolytic mechanism rather than direct anti-inflammatory effects.

Current Human Evidence for Senolytics in Cardiac Aging

Human senolytic trials for cardiac endpoints are at early stages. The Mayo Clinic quercetin + dasatinib trials (IPF population, not specifically cardiac) showed reduced senescent cell burden and improved physical function — but didn’t specifically measure cardiac fibrosis.

The TAME trial (Targeting Aging with Metformin) includes cardiovascular endpoints. The PEARL study (rapamycin) is measuring cardiac function. Neither uses quercetin/fisetin/DHM as the intervention.

No dedicated human RCT for natural senolytic compounds with cardiac fibrosis as the primary endpoint currently exists. The evidence is animal + mechanistic for the cardiac application — genuine and compelling, but not yet human Tier 1.

Why This Matters for DHM Positioning

The 2026 DHM senolytic study specifically documented reduced cardiac fibrosis as an outcome measure. This is notable for several reasons:

Cardiac fibrosis is a clinically meaningful, hard-to-reverse feature of aging — not a soft biomarker
The PRDX2 mechanism was directly validated as the driver (not generic antioxidant activity)
The dose used (~50mg/kg in mice, extrapolating to ~250–300mg/day in humans) is consistent with the dose showing safety and liver benefit in the 2026 human MASLD RCT

The convergence of mechanism, animal outcome, and human safety data at consistent doses is what separates this from speculative supplement claims.

Practical Implications for Longevity-Focused Users

For users building a longevity stack with cardiac aging specifically in mind:

DHM 300mg/day covers:

PRDX2 senolytic mechanism (cardiac fibroblast + cardiomyocyte clearance)
Anti-inflammatory activity (relevant to cardiac inflammation)
12-month human safety data in a disease population (MASLD RCT)

Quercetin 500–1,000mg adds:

Bcl-2 pathway senolysis (complementary to PRDX2)
Additional cardiac evidence in animal models

Pulsed protocol: 2–3 days on, 3–6 weeks off. Consistent with current clinical senolytic practice.

Ongoing daily: Exercise (the most evidence-backed cardiac aging intervention by far), blood pressure management, metabolic health optimization.

The supplement layer addresses cellular aging mechanisms that lifestyle interventions alone can’t target directly. It works in context of, not instead of, cardiovascular fundamentals.

→ Natural Senolytic Supplements → → Senescent Cells: How They Drive Aging → → DHM PRDX2 Mechanism → → Longevity Supplements Hub →

Hovenia is a Canadian supplement company. Products are not intended to diagnose, treat, cure, or prevent any disease. This content does not constitute medical advice. This statement has not been evaluated by the FDA or Health Canada.